Badania porównawcze wpływu rabeprazolu vs omeprazolu na wydzielanie kwasu żołądkowego i sluzowo-elektrolitowe u pacjentów z chorobą wrzodową

Autor

  • Helena Sklyarova Danylo Halytskyi Lviv National Medical University, Outpatient and Family Department, Ukraine Autor
  • Irena Shalko Danylo Halytskyi Lviv National Medical University, Outpatient and Family Department, Ukraine Autor

Słowa kluczowe:

wrzód żołądka, rabeprazol, omeprazol

Abstrakt

Rabeprazol zapewnia lepszą supresję kwasu i hamowanie uwalniania pepsyny niż omeprazol. Lepsze wyniki leczenia wrzodów po zastosowaniu rabeprazolu w porównaniu z omeprazolem spowodowane są jego wpływem ochronnym na śluzówkę żołądka.

Bibliografia

1. Dekkers C.P. et al.: Comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of active gastric ulcer—a European multicentre study. The European Rabeprazole Study Group. Aliment. Pharmacol. Ther., 12, 789, 1998.

2. Horn J.: Review article: Relationship between the metabolism and efficacy of proton pump inhibitors—focus on rabeprasole. Aliment Pharmacol. Ther., 20, 9, 2004.

3. Ji S. et al.: Comparison of the efficacy of rabeprazole 10 mg and omeprazole 20 mg for the healing rapidity of peptic ulcer disease. J. Gastroenterol. Hepatol., 21, 1381, 2006.

4. Klotz U.: Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem. Int. J. Clin. Pharmacol. Ther. 44, 297, 2006.

5. Miner P.Jr. et al.: Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am. J. Gastroenterol., 98, 2616, 2003.

6. Ohning G.V. et al.: Rabeprazole is superior to omeprazole for the inhibition of pepton meal-stimulated gastric acid secretion in Helicobacter pylori-negative subjects. Aliment. Pharmacol. Ther., 17, 1109, 2003.

7. Saitoh T. et al.: Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers. Aliment. Pharmacol. Ther., 16, 1811, 2002.

8. Sharara A.I.: Rabeprazole: the role of proton pump inhibitors in Helicobacter pylori eradication. Expert. Rev. Anti. Infect. Ther., 3, 863, 2005.

9. Shimatani T. et al.: Acid-suppressive efficacy of a reduced dosage of rabeprazole: comparison of 10 mg twice daily rabeprazole with 20 mg twice daily rabeprazole, 30 mg twice daily lansoprazole, and 20 mg twice daily omeprazole bu 24-hr intragastric pH-metry. Dig. Dis. Sci., 50, 1202, 2005.

10. Williams M.P.: Eradication of Helicobacter pylori increases nocturnal intragastric acidity during dosing with rabeprazole, omeprazole, lansoprazole and placebo. Aliment. Pharmacol. Ther., 15, 775, 2003.

Pobrania

Opublikowane

2010-09-30

Numer

Tom 23 Nr 3 (2010): Annales UMCS, Pharmacia, Sectio DDD, Volume XXIII, N3

Dział

Artykuły

Licencja

Prawa autorskie (c) 2010 Autorzy

Creative Commons License

Praca jest udostępniana na licencji Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 Unported License.